Type 1 Interferons and the Virus-Host Relationship: A Lesson in Detente, Science, vol.312, issue.5775, pp.879-882, 2006. ,
DOI : 10.1126/science.1125676
Antiviral defense: interferons and beyond: Figure 1., The Journal of Experimental Medicine, vol.152, issue.8, pp.1837-1841, 2006. ,
DOI : 10.1073/pnas.0601523103
Type I IFN Receptor Signals Directly Stimulate Local B Cells Early following Influenza Virus Infection, The Journal of Immunology, vol.176, issue.7, pp.4343-4351, 2006. ,
DOI : 10.4049/jimmunol.176.7.4343
Cutting Edge: Type I IFNs Provide a Third Signal to CD8 T Cells to Stimulate Clonal Expansion and Differentiation, The Journal of Immunology, vol.174, issue.8, pp.4465-4469, 2005. ,
DOI : 10.4049/jimmunol.174.8.4465
Plasmacytoid Dendritic Cells Induce Plasma Cell Differentiation through Type I Interferon and Interleukin 6, Immunity, vol.19, issue.2, pp.225-234, 2003. ,
DOI : 10.1016/S1074-7613(03)00208-5
Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection, The Journal of Experimental Medicine, vol.4, issue.5, pp.637-650, 2005. ,
DOI : 10.1038/37648
DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL, Nature Immunology, vol.3, issue.9, pp.822-829, 2002. ,
DOI : 10.1038/ni829
Potent and Selective Stimulation of Memory-Phenotype CD8+ T Cells In Vivo by IL-15, Immunity, vol.8, issue.5, pp.591-599, 1998. ,
DOI : 10.1016/S1074-7613(00)80564-6
Interferon-producing Cells Fail to Induce Proliferation of Naive T Cells but Can Promote Expansion and T Helper 1 Differentiation of Antigen-experienced Unpolarized T Cells, The Journal of Experimental Medicine, vol.66, issue.7, pp.899-906, 2003. ,
DOI : 10.1078/0171-2985-00092
Critical Role for STAT4 Activation by Type 1 Interferons in the Interferon-gamma Response to Viral Infection, Science, vol.297, issue.5589, pp.2063-2066, 2002. ,
DOI : 10.1126/science.1074900
Type I Interferons Potently Enhance Humoral Immunity and Can Promote Isotype Switching by Stimulating Dendritic Cells In Vivo, Immunity, vol.14, issue.4, pp.461-470, 2001. ,
DOI : 10.1016/S1074-7613(01)00126-1
Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon, Nature Immunology, vol.4, issue.10, pp.1009-1015, 2003. ,
DOI : 10.1038/ni978
Type I interferons produced by dendritic cells promote their phenotypic and functional activation, Blood, vol.99, issue.9, pp.3263-3271, 2002. ,
DOI : 10.1182/blood.V99.9.3263
Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection, Journal of Clinical Investigation, vol.116, issue.11, pp.3006-3014, 2006. ,
DOI : 10.1172/JCI29832DS1
A multicenter randomized controlled trial of recombinant interferon-??2b in patients with acute transfusion-associated hepatitis C, Hepatology, vol.16, issue.1, pp.19-22, 1994. ,
DOI : 10.1002/hep.1840190105
Cutting Edge: Enhancement of Antibody Responses Through Direct Stimulation of B and T Cells by Type I IFN, The Journal of Immunology, vol.176, issue.4, pp.2074-2078, 2006. ,
DOI : 10.4049/jimmunol.176.4.2074
IFN-?? Induces Early Lethal Lupus in Preautoimmune (New Zealand Black x New Zealand White)F1 but Not in BALB/c Mice, The Journal of Immunology, vol.174, issue.5, pp.2499-2506, 2005. ,
DOI : 10.4049/jimmunol.174.5.2499
Type I IFN as a Natural Adjuvant for a Protective Immune Response: Lessons from the Influenza Vaccine Model, The Journal of Immunology, vol.169, issue.1, pp.375-383, 2002. ,
DOI : 10.4049/jimmunol.169.1.375
Type-I Interferon Receptor Deficiency Reduces Lupus-like Disease in NZB Mice, The Journal of Experimental Medicine, vol.154, issue.6, pp.777-788, 2003. ,
DOI : 10.1038/ni0901-785
Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon, New England Journal of Medicine, vol.354, issue.7, pp.709-718, 2006. ,
DOI : 10.1056/NEJMoa053007
TYPE I INTERFERONS (??/??) IN IMMUNITY AND AUTOIMMUNITY, Annual Review of Immunology, vol.23, issue.1, pp.307-336, 2005. ,
DOI : 10.1146/annurev.immunol.23.021704.115843
Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN : results from the Primoferon A (ANRS 086) Study, Primoferon A Study Group. AIDS, vol.15, pp.1435-1437, 2001. ,
Impact of highly active antiretroviral therapy on the maturation of anti-HIV-1 antibodies during primary HIV-1 infection, HIV Medicine, vol.103, issue.8, pp.514-519, 2006. ,
DOI : 10.1046/j.1365-2249.2000.01144.x
Detection of peripheral HIV-1-specific memory B cells in patients untreated or receiving highly active antiretroviral therapy, AIDS, vol.17, issue.16, pp.2323-2330, 2003. ,
DOI : 10.1097/00002030-200311070-00006
Type I Interferon Production Is Profoundly and Transiently Impaired in Primary HIV???1 Infection, The Journal of Infectious Diseases, vol.192, issue.2, pp.303-310, 2005. ,
DOI : 10.1086/430931
Dendritic Cells in Innate Immune Responses Against HIV, Current Molecular Medicine, vol.2, issue.8, pp.739-756, 2002. ,
DOI : 10.2174/1566524023361907
Stimulation of anti-HIV antibody response by ,
URL : https://hal.archives-ouvertes.fr/inserm-00263595
Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions, AIDS, vol.19, issue.17, pp.1947-1955, 2005. ,
DOI : 10.1097/01.aids.0000191231.54170.89
Potent Immune Response against HIV-1 and Protection from Virus Challenge in hu-PBL-SCID Mice Immunized with Inactivated Virus-pulsed Dendritic Cells Generated in the Presence of IFN-??, The Journal of Experimental Medicine, vol.160, issue.2, pp.361-367, 2003. ,
DOI : 10.1038/85493
Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity in Vitro and in Hu-Pbl-Scid Mice, The Journal of Experimental Medicine, vol.162, issue.10, pp.1777-1788, 2000. ,
DOI : 10.1038/32183
BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells, The Journal of Experimental Medicine, vol.157, issue.1, pp.91-97, 2004. ,
DOI : 10.1038/nsb769
BAFF selectively enhances the survival of plasmablasts generated from human memory B cells, Journal of Clinical Investigation, vol.112, issue.2, pp.286-297, 2003. ,
DOI : 10.1172/JCI18025
Interleukin-12 and the regulation of innate resistance and adaptive immunity, Nature Reviews Immunology, vol.3, issue.2, pp.133-146, 2003. ,
DOI : 10.1038/nri1001
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection, Nat. Med, vol.6, pp.200-206, 2000. ,
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection, Proc. Natl. Acad. Sci. USA, pp.18514-18519, 2005. ,
DOI : 10.1073/pnas.0504658102
Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1, Nature Medicine, vol.10, issue.12, pp.1389-1393, 1997. ,
DOI : 10.1038/nm1297-1389
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites, Nature, vol.85, issue.6916, pp.678-682, 2002. ,
DOI : 10.1128/JVI.74.4.1961-1972.2000
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies, AIDS, vol.15, pp.207-210, 2000. ,
DOI : 10.1097/00002030-200102001-00018
Rapid evolution of the neutralizing antibody response to HIV type 1 infection, Proc. Natl. Acad. Sci. USA, pp.4144-4149, 2003. ,
DOI : 10.1073/pnas.0630530100
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys, Nature Medicine, vol.5, issue.2, pp.204-210, 1999. ,
DOI : 10.1038/5568
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies, Nature Medicine, vol.14, issue.6, pp.615-622, 2005. ,
DOI : 10.1016/j.virol.2004.05.022
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120, Nature Medicine, vol.9, issue.3, pp.343-346, 2003. ,
DOI : 10.1038/nm833
Effects of a Combination of Zidovudine, Didanosine, and Lamivudine on Primary Human Immunodeficiency Virus Type 1 Infection, The Journal of Infectious Diseases, vol.175, issue.5, pp.1051-1055, 1997. ,
DOI : 10.1086/516442
The Effect of Commencing Combination Antiretroviral Therapy Soon after Human Immunodeficiency Virus Type 1 Infection on Viral Replication and Antiviral Immune Responses, The Journal of Infectious Diseases, vol.179, issue.3, pp.527-537, 1999. ,
DOI : 10.1086/314628
Competence and competition: the challenge of becoming a long-lived plasma cell, Nature Reviews Immunology, vol.106, issue.10, pp.741-750, 2006. ,
DOI : 10.1038/nri1886
Antibody neutralization and escape by HIV-1, Nature, vol.422, issue.6929, pp.307-312, 2003. ,
DOI : 10.1038/nature01470
Detection of Antibody-Dependent Complement-Mediated Inactivation of both Autologous and Heterologous Virus in Primary Human Immunodeficiency Virus Type 1 Infection, Journal of Virology, vol.79, issue.5, pp.2823-2830, 2005. ,
DOI : 10.1128/JVI.79.5.2823-2830.2005
HIV-Specific Cellular and Humoral Immune Responses in Primary HIV Infection, AIDS Research and Human Retroviruses, vol.12, issue.12, pp.1129-1140, 1996. ,
DOI : 10.1089/aid.1996.12.1129
Antibody from Patients with Acute Human Immunodeficiency Virus (HIV) Infection Inhibits Primary Strains of HIV Type 1 in the Presence of Natural-Killer Effector Cells, Journal of Virology, vol.75, issue.15, pp.6953-6961, 2001. ,
DOI : 10.1128/JVI.75.15.6953-6961.2001
Complement Lysis Activity in Autologous Plasma Is Associated with Lower Viral Loads during the Acute Phase of HIV-1 Infection, PLoS Medicine, vol.99, issue.11, p.441, 2006. ,
DOI : 10.1371/journal.pmed.0030441.st001